Comparative analysis of the quality of platelet concentrates produced by apheresis procedures, platelet rich plasma, and buffy coat
© 2024 AABB..
BACKGROUND: Platelet concentrates (PCs) could be prepared using either whole-blood processes or apheresis instruments. During collection, processing and storage, some biochemical and functional changes occur, which may result in quality reduction. Quality evaluation of PCs may be helpful for the precise control of platelet (PLT) inventory to reduce the risk of refractoriness and adverse effects caused by platelet transfusion.
STUDY DESIGN AND METHODS: The study was aimed to evaluate the quality of PCs which were produced by five processes: apheresis (AP) procedures (using three different cell separators: Amicus, Trima Accel and MCS+ instruments), platelet rich plasma (PRP), and buffy coat (BC). A total of 100 PCs (20 of each group) were assessed in respect of routine quality control, morphology, size distribution, destroyed and activated platelets, and production of platelet-derived microparticles (PMPs).
RESULTS: All PCs have satisfied the recommended quality of volume, platelet count, residual WBC count, residual RBC count, pH, and sterility according to the Chinese Technical Manual. There was no difference among the 5 groups in morphology and size of PLT and PMPs. Dynamic light scattering test showed that apheresis PCs showed peaks around 10-20 nm, but not whole blood-derived PCs. PCs prepared by Amicus had the relatively high percentage of destroyed platelet, activated platelets and PMPs than other groups.
DISCUSSION: The data suggested high heterogeneity of PMPs, destroyed and activated platelets in PCs produced by different processes, which might be helpful to manage the platelet inventory for targeted use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Transfusion - 64(2024), 2 vom: 01. Feb., Seite 367-379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Meng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Activated platelets |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/trf.17704 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366650572 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366650572 | ||
| 003 | DE-627 | ||
| 005 | 20240301232303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/trf.17704 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM366650572 | ||
| 035 | |a (NLM)38174435 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Meng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative analysis of the quality of platelet concentrates produced by apheresis procedures, platelet rich plasma, and buffy coat |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 AABB. | ||
| 520 | |a BACKGROUND: Platelet concentrates (PCs) could be prepared using either whole-blood processes or apheresis instruments. During collection, processing and storage, some biochemical and functional changes occur, which may result in quality reduction. Quality evaluation of PCs may be helpful for the precise control of platelet (PLT) inventory to reduce the risk of refractoriness and adverse effects caused by platelet transfusion | ||
| 520 | |a STUDY DESIGN AND METHODS: The study was aimed to evaluate the quality of PCs which were produced by five processes: apheresis (AP) procedures (using three different cell separators: Amicus, Trima Accel and MCS+ instruments), platelet rich plasma (PRP), and buffy coat (BC). A total of 100 PCs (20 of each group) were assessed in respect of routine quality control, morphology, size distribution, destroyed and activated platelets, and production of platelet-derived microparticles (PMPs) | ||
| 520 | |a RESULTS: All PCs have satisfied the recommended quality of volume, platelet count, residual WBC count, residual RBC count, pH, and sterility according to the Chinese Technical Manual. There was no difference among the 5 groups in morphology and size of PLT and PMPs. Dynamic light scattering test showed that apheresis PCs showed peaks around 10-20 nm, but not whole blood-derived PCs. PCs prepared by Amicus had the relatively high percentage of destroyed platelet, activated platelets and PMPs than other groups | ||
| 520 | |a DISCUSSION: The data suggested high heterogeneity of PMPs, destroyed and activated platelets in PCs produced by different processes, which might be helpful to manage the platelet inventory for targeted use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a activated platelets | |
| 650 | 4 | |a destroyed platelets | |
| 650 | 4 | |a platelet concentrates | |
| 650 | 4 | |a platelet-derived microparticles | |
| 650 | 4 | |a quality | |
| 700 | 1 | |a Zhao, Yuwei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Xinman |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Jianxun |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Like |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jingyun |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Xuemei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion |d 1961 |g 64(2024), 2 vom: 01. Feb., Seite 367-379 |w (DE-627)NLM00001107X |x 1537-2995 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:367-379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/trf.17704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |e 2 |b 01 |c 02 |h 367-379 | ||